What are the detailed instructions for pazopanib/pazopanib?

1. Overview of drugs

Pazopanib/Pazopanib , trade nameVOTRIENT, is an oral multi-target tyrosine kinase inhibitor (TKI) developed by GlaxoSmithKline (GSK). The drug mainly inhibits tumor angiogenesis and tumor growth by inhibiting multiple kinases such as vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and stem cell factor receptor (c-KIT). The drug is approved for the treatment of advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma (STS), specifically for patients who are resistant to first-line treatments.

2. Indications

1. Advanced renal cell carcinoma (RCC): Applicable to adult patients, including patients with untreated advanced or metastatic renal cell carcinoma, and also applicable to patients who have received cytokine therapy but whose disease has progressed.

2. Advanced soft tissue sarcoma (STS): It is suitable for adult patients with advanced soft tissue sarcoma who have received chemotherapy. Especially for patients who have not received angiogenesis inhibitor treatment, pazopanib can be used as a second-line treatment option.

3. Usage and dosage

1. Recommended dosage: Once a day, each time 800mg (4 tablets of 200mg), orally.

2. How to take: Take on an empty stomach (at least 1 hour before a meal or 2 hours after a meal).

3. Taking time: It is recommended to take the medicine at the same time every day to maintain stable blood concentration.

4. Dose adjustment: If intolerable side effects occur, the dose can be reduced to 600mg or 400mg, once a day. Based on the patient's tolerance, the doctor may further adjust the dose.

5. Treatment duration: Until disease progression or intolerable toxicity occurs.

4. Pharmacological effects

Pazopanib is a multi-target tyrosine kinase inhibitor that exerts anti-tumor effects by inhibiting the following key pathways:

VEGFR-1/2/3 (vascular endothelial growth factor receptor): Its main function is to inhibit tumor angiogenesis, reduce tumor blood supply, and prevent tumor spread.

PDGFR-α/β (platelet-derived growth factor receptor): affects the growth of tumor stroma and inhibits the proliferation of tumor cells.

c-KIT (stem cell factor receptor): Mainly plays an important role in GIST (gastrointestinal stromal tumor) and certain sarcomas. Pazopanib can reduce the growth signal of tumor cells by inhibiting c-KIT.

By blocking the above-mentioned signaling pathways, pazopanib can effectively inhibit tumor angiogenesis and cell proliferation, thereby delaying tumor progression.

5. Adverse reactions and management

Common side effects of pazopanib include: abnormal liver function (ALT, AST, and bilirubin elevation), hypertension, gastrointestinal reactions (nausea, vomiting, diarrhea, decreased appetite), hand and foot skin reactions (the skin may appear red, swollen, peeling, and stinging), thyroid dysfunction (hypothyroidism or hyperthyroidism), proteinuria, prolongation QT interval, and increased risk of bleeding (epistaxis, gastrointestinal bleeding).

6. Storage and precautions

1. Storage conditions: Below 25°C, avoid moisture and direct sunlight.

2. Packaging specifications: 200 mg/tablet, 30 tablets/bottle.

3. Precautions: Blood pressure, liver function, electrocardiogram and other indicators should be monitored regularly during medication. Avoid drinking grapefruit juice to prevent it from affecting drug metabolism. If serious side effects occur, you need to communicate with your doctor promptly to adjust the dosage or change the treatment plan.

Reference materials:https://www.votrient.com/